Table 1.
Main characteristics of the 11 studies in the meta-analysis.
| Study | Country | Year | Sample | Study design | Sizes | Cut-off value | Gender (female/male) | Follow-up time (month) | Tumor stage (I/II/III/IV) | Outcome | Method | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dundas, S. et al. | Britain | 2005 | CRC | R | 231 | 25% | NA | 0-120 | NA | OS | IHC | 7 |
| Graf, L. et al. | Hungary | 2018 | CRC | R | 232 | 20% | 112/120 | 0-60 | NA | OS | IHC | 7 |
| Jubran, R. et al. | Hungary | 2017 | CRC | R | 227 | NR | 121/106 | 0-60 | 30/40/60/97 | OS | IHC | 8 |
| Kocsis, J. et al. | Hungary | 2009 | CRC | R | 178 | NR | 89/88 | 33 (24-44) | 25/26/60/67 | OS | IHC | 9 |
| Kocsis, J. et al. | Hungary | 2010 | CRC | R | 254 | NR | NA | 33.0 (23.5–43.5) | 80/60/110/4 | OS | IHC | 8 |
| Lazaris, A. et al. | Greece | 1997 | CRC | R | 128 | 25% | NA | 44.76 (0-222.36) | NA | OS | IHC | 9 |
| Jogi, A. et al. | Sweden | 2009 | CRC | R | 196 | 25% | NA | 0-60 | NA | OS | IHC | 8 |
| Shotar, A. et al. | Jordan | 2005 | CRC | R | 215 | 20% | 112/103 | 6.88 (0.64-17.05) | 40/32/79/64 | OS | IHC | 8 |
| Sun, X. et al. | Sweden | 1997 | CRC | R | 256 | 20% | 122/134 | 0-156 | NA | OS | IHC | 7 |
| Kim, J. et al. | Korea | 2014 | CRC | R | 167 | 25% | NA | 29 (0-120) | NA | DFS | IHC | 9 |
| Oh, H. et al. | Korea | 2017 | CRC | R | 185 | NR | 90/95 | 51.1 (3.1-57.1) | NA | DFS | IHC | 9 |
Abbreviation: CRC: colorectal cancer; R: retrospective analysis; NR: not report; OS: overall survival; DFS: disease-free survival; IHC: immunohistochemistry; NA: not available; NOS: Newcastle-Ottawa Scale.